Xiangguang Shi, Yahui Chen, Mengkun Shi, Fei Gao, Lihao Huang, Wei Wang, Dong Wei, Chenyi Shi, Yuexin Yu, Xueyi Xia, Nana Song, Xiaofeng Chen, Jörg H W Distler, Chenqi Lu, Jingyu Chen, Jiucun Wang
Pulmonary fibrosis (PF) is a severe pulmonary disease with limited available therapeutic choices. Recent evidence increasingly points to abnormal lipid metabolism as a critical factor in PF pathogenesis. Our latest research identifies the dysregulation of low-density lipoprotein (LDL) is a new risk factor for PF, contributing to alveolar epithelial and endothelial cell damage, and fibroblast activation. In this study, we first integrative summarize the published literature about lipid metabolite changes found in PF, including phospholipids, glycolipids, steroids, fatty acids, triglycerides, and lipoproteins...
April 3, 2024: Lipids in Health and Disease